Gclm — Glutamate Cysteine Ligase Modifier Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| GCLM — Glutamate-Cysteine Ligase Modifier Subunit | |
|---|---|
| Symbol | GCLM |
| Full Name | Glutamate-Cysteine Ligase Modifier Subunit |
| Chromosome | 1p22.1 |
| NCBI Gene | 2739 |
| Ensembl | ENSG00000100916 |
| OMIM | 606466 |
| UniProt | P48507 |
| Diseases | Parkinson's Disease, Alzheimer's Disease, Oxidative Stress |
| Expression | Liver, Kidney, Brain, Lung |
GCLM (Glutamate-Cysteine Ligase Modifier Subunit) is a gene located on chromosome 1p22.1 that encodes the modifier subunit of glutamate-cysteine ligase (GCL), the rate-limiting enzyme in glutathione biosynthesis. GCL catalyzes the first step in the synthesis of glutathione (GSH), a crucial antioxidant that protects cells from oxidative damage. The enzyme consists of a catalytic subunit (GCLC) and a modifier subunit (GCLM), which together regulate cellular glutathione levels.
GCLM forms a heterodimer with GCLC (glutamate-cysteine ligase catalytic subunit) to create functional glutamate-cysteine ligase. The modifier subunit:
Glutathione is essential for:
Parkinson's Disease: GCLM variants and reduced GCLM expression have been associated with PD risk. Glutathione deficiency in the substantia nigra of PD patients may contribute to dopaminergic neuron vulnerability.
Alzheimer's Disease: Oxidative stress plays a key role in AD pathogenesis. GCLM polymorphisms may influence antioxidant capacity and disease progression.
Amyotrophic Lateral Sclerosis (ALS): GCLM variants may modify disease onset and progression in some familial ALS cases.
Huntington's Disease: GCLM expression changes have been observed in HD models, affecting glutathione metabolism.
The study of Gclm — Glutamate Cysteine Ligase Modifier Subunit has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.